Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066792 · ClinicalTrials.gov registry record · Early Phase 1
Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
A Early Phase 1 study, sponsored by Jasper A. Smits.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 152
- Enrollment target
NCT02066792: Completed Early Phase 1 study, sponsored by Jasper A. Smits.
NCT02066792 is a Early Phase 1 study that has completed, run by Jasper A. Smits. The registered enrollment target is 152 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (187% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066792, a Early Phase 1 study, has completed, sponsored by Jasper A. Smits.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the efficacy of 50 mg of d-cycloserine in comparison to placebo (a pill containing no medication) for improving the effectiveness of cognitive-behavioral therapy (CBT) in reducing symptoms associated with social anxiety disorder. In addition, the study will examine whether the effectiveness of d-cycloserine depends on the timing of the pill administration (i.e., 1- hour before the session or immediately after the session) as well as the success of the CBT therapy sessions. The investigators hypothesize that the tailored post-session DCS administration condition will outperform the other conditions (pre-session DCS, placebo, and non-tailored post-session DCS). This will be evidenced by short- and long-term improvements in social anxiety severity.
Primary Outcome
The main outcome was a composite Z-score from the Liebowitz Social Anxiety Scale (LSAS) and the Social Phobic Disorders Severity and Change Form (SPD-SC Form). "The Composite Z-score of the LSAS and SPD-SC Form indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower symptom severity and positive numbers indicate higher symptom severity. The LSAS is a 24-item scale that measures fear an
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive Behavioral Therapy
- DRUG D-Cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-07-01 |
| Phase | Early Phase 1 |
What the finished NCT02066792 record still lists
NCT02066792 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (187% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02066792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02066792 about?
NCT02066792 is a clinical study titled "Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder". The purpose of this study is to examine the efficacy of 50 mg of d-cycloserine in comparison to placebo (a pill containing no medication) for improving the effectiveness of cognitive-behavioral therapy (CBT) in reducing symptoms associated with social anxiety disorder. In addition, the study will ex...
What is the current status of trial NCT02066792?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 152 participants. The study started on 2014-04. Estimated completion is 2018-07-01.
What interventions are being tested in trial NCT02066792?
The interventions under investigation include: Placebo (DRUG), Cognitive Behavioral Therapy (BEHAVIORAL), D-Cycloserine (DRUG).
Who is sponsoring clinical trial NCT02066792?
This trial is sponsored by Jasper A. Smits, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02066792's enrollment target sits among peer trials
152 98th of 2000 higher than 1,902 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia